World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”), is pleased to report the operating and financial results for its year ended April 30, 2020

Company Summary

World-Class is an innovation-driven company with a principle focus on the evolving cannabis and hemp industries. Through its subsidiaries, World-Class is working on partnerships to deploy and manage custom-built extraction centres utilizing its custom systems, technology, and processes to efficiently produce high-quality cannabis and hemp concentrates and end-products.

In addition, Pineapple Express Delivery (“PED“), a company in which the Company holds a controlling interest, offers compliant and secure delivery of government regulated products, including medical and recreational cannabis in Ontario, Manitoba and Saskatchewan, and liquor delivery in certain jurisdictions in Saskatchewan.

On July 29, 2020, World-Class announced that a company in which World-Class holds a 50% equity interest, Cobra Ventures Inc. (“Cobra“), entered into an agreement to acquire a senior secured convertible debenture of HydRx Farms Ltd. operating as Scientus Pharma (“HydRx“) in the principal amount of CDN$11,500,000, plus accrued and unpaid interest and charges (the “Debenture“) from a leading Canadian Licensed Producer, subject to certain closing conditions. Cobra is purchasing the Debenture for CDN$5,000,000.

Financial (audited)

  • Revenue of $1,108,292 for the year ended April 30, 2020 compared to nil revenue for the year ended April 30, 2019. Gross margin for the year ended April 30, 2020 was 47%.
  • The Company had cash as at April 30, 2020 of $5,632,160 (April 30, 2019 – $16,002,152) and current assets of $8,503,914 (April 30, 2019 – $20,957,680) to settle current liabilities of $5,493,417 (April 30, 2019 – $325,281). $3,018,134 of the current liabilities relate to convertible debt of $1,996,405 and resulting derivative liability of $1,021,729 assumed pursuant to the PED acquisition.
  • The net loss and comprehensive loss for the year ended April 30, 2020 was $48,539,965 (as compared to April 30, 2019 of $12,354,999). The increased loss for the year is mainly attributed to the following:
    • Due to downturn in the cannabis market and management’s decision to deprioritize the development of the ultrasonic intellectual property technology, there is uncertainty in the realization of future economic benefits from this intellectual property. As a result, the Company assessed and recognized $7,773,287 in impairment charge against the value of this asset which is equivalent to 100% of its carrying amount.
    • Due to uncertainty on the realization of future economic benefits from the ultrasonic technology the patent that relates to the technology was also impaired. As a result, the Company recognized an impairment charge of $101,367 relating to this ultrasonic patent in the statement of loss and comprehensive loss.
    • The Company assessment of the value of the goodwill associated with the QCC acquisition amounted to $Nil and hence, an impairment loss equal to $20,450,690 was recognized in the statement of loss and comprehensive loss for the year. Impairment is attributed to a downturn in the cannabis market, declining extraction equipment sales and uncertainty of future economic benefits. The remaining goodwill relates to goodwill assumed upon acquisition of PED.
    • In addition, the loss includes a write down of inventories of $3,406,415, depreciation and amortization expense of $2,375,327. Selling expenses totaled $1,108,292 (April 30, 2019 – $1,162,615). General and administrative expenses totaling $9,293,522 (April 30, 2019 – $3,334,014) included the following notable expenses, consulting fees of $758,880 (April 30, 2019 – $707,996); development and research expenses of $1,728,755 (April 30, 2019 – $81,026); office expenses of $182,119 (April 30, 2019 – $19,834), professional fees of $1,103,618 (April 30, 2019 – $384,859); rent of $189,331 (April 30, 2019 – $21,983), remuneration and benefits of $2,133,478 (April 30, 2019 – $Nil); and share-based payments of $2,468,231 (April 30, 2019 – $1,864,786).

Rosy Mondin, CEO of World-Class stated: “World-Class has seen a 100% increase in its revenues from prior periods and we anticipate seeing triple-digit revenue growth for the rest of the year. By maximizing the capabilities of our subsidiaries we’ve been able to capitalize on their successes and the important role they play in supporting the growth of the Canadian cannabis industry. We are pleased with the strong growth from PED – since our acquisition of a controlling interest in PED in March 2020, PED continues to expand its service jurisdictions as well as its delivery of controlled substances, to now include wine, spirits and beer delivery in addition to recreational, medical and B2B cannabis delivery. To further support medical cannabis delivery to patients, PED partnered with Medical Cannabis by Shoppers™ and Spectrum Therapeutics, the medical division of Canopy Growth Corporation. The Soma team completed the commissioning of an independent mobile processing system which efficiently sorts, pelletizes, bags and oxygen-purges acres of hemp crop in hours. In addition, the Company is taking advantage of opportunities to monetize and deploy its extraction systems, and as announced in July 2020 we are purchasing a first position Debenture registered against the assets of HydRx Farms Inc.”

“For this year-end,” Ms. Mondin continued, “we have taken a extremely conservative accounting approach resulting in the impairment of our intangible assets. World-Class’ cash position provides us the flexibility to meet operational obligations, while we pursue other opportunities that may arise during this period of volatility. Management remains hyper-focused as we strategically position ourselves to capitalize on the opportunities ahead in the pursuit of shareholder value. The downturn in the cannabis and hemp industries which began in 2019, and further amplified by the COVID-19 pandemic has certainly presented its challenges but our World-Class teams continue to execute on our growth strategy. We are proud of our ability to adapt and pivot to meet today’s market realities. The steps taken this past year will result in a leaner and stronger company that will continue to innovate, maximize production and reduce costs and be a strong industry competitor.”

About World-Class

World- Class is an innovation-driven company with a principle focus on the rapidly evolving cannabis and hemp industries. Through its subsidiaries Soma Labs Scientific Inc. and Greenmantle Products Inc., World-Class deploys and manages custom-built extraction centres utilizing its custom systems, technology, and processes to efficiently produce high-quality cannabis and hemp concentrates and end-products. In addition, through its subsidiary Pineapple Express Delivery Inc. the Company offers compliant and secure delivery of government regulated products, including medical and recreational cannabis in Ontario, Manitoba and Saskatchewan, and liquor delivery in certain jurisdictions in Saskatchewan.

Investor Contact

Daniel Mogil
World-Class Investor Relations
(437) 266-1969

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the ability of Cobra to close on the acquisition of the Debenture. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

SOURCE: World-Class Extractions Inc.

View source version on

News Provided by ACCESSWIRE via QuoteMedia

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less